RedChip to Hold Exclusive Webinar Focusing on Lantern Pharma on August 26

Summary

Lantern Pharma will be featured in an exclusive investor webinar hosted by RedChip Companies on August 26, 2025, at 4:15 p.m. ET. The webinar will focus on Lantern’s innovative AI platform, RADR®, which improves cancer drug development efficiency. Lantern’s clinical pipeline includes LP-300 for NSCLC, LP-184 for DDR-deficient tumors, and LP-284 for aggressive lymphomas. The session will include a live Q&A with management. RedChip specializes in investor relations for microcap and small-cap companies, providing services to enhance investor engagement.Acceswire

Impact Analysis

The event is classified at the company level, focusing on Lantern Pharma’s advancements in AI-driven drug development. First-order effects include increased investor interest in Lantern Pharma due to the innovative RADR® platform and its implications for cancer treatment advancements. The webinar provides an opportunity for investors to engage directly with management, gaining insights into the company’s pipeline and strategic direction. Second-order effects may involve heightened attention to AI applications in healthcare and potential collaborations or investments in the sector. Investment opportunities lie in Lantern Pharma’s stock, particularly if the webinar successfully communicates its technological edge and growth potential in oncology drug development.Acceswire